# EDGAR Filing Document

**Accession Number:** 0001001316
**File Stem:** 0001437749-26-020491
**Filing Date:** 2026-6
**Character Count:** 6314
**Document Hash:** 7b43775f7596f06f0d7c095552121ade
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001437749-26-020491.hdr.sgml**: 20260612

**ACCESSION NUMBER**: 0001437749-26-020491

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 12

**CONFORMED PERIOD OF REPORT**: 20260611

**ITEM INFORMATION**: Submission of Matters to a Vote of Security Holders

**FILED AS OF DATE**: 20260612

**DATE AS OF CHANGE**: 20260612

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** TG THERAPEUTICS, INC.
- **CENTRAL INDEX KEY:** 0001001316
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 363898269
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-32639
- **FILM NUMBER:** 261087312

**BUSINESS ADDRESS:**
- **STREET 1:** 2 GANSEVOORT STREET, 9TH FLOOR
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10014
- **BUSINESS PHONE:** (212) 554-4484

**MAIL ADDRESS:**
- **STREET 1:** 2 GANSEVOORT STREET, 9TH FLOOR
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10014

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** MANHATTAN PHARMACEUTICALS INC
- **DATE OF NAME CHANGE:** 20030310

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** ATLANTIC TECHNOLOGY VENTURES INC
- **DATE OF NAME CHANGE:** 20000330

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** ATLANTIC PHARMACEUTICALS INC
- **DATE OF NAME CHANGE:** 19960703

?xml version='1.0' encoding='ASCII'? tgtx20260612_8k.htm

------

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

------

**FORM 8-K**

------

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the**

**Securities Exchange Act of 1934**

Date of report (Date of earliest event reported): **June 11, 2026**

**TG Therapeutics, Inc.**

(Exact Name of Registrant as Specified in Charter)

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-32639** | **36-3898269** |
| (State or Other Jurisdiction | (Commission File Number) | (IRS Employer Identification No.) |
| of Incorporation) |  |  |

---

**3020 Carrington Mill Blvd, Suite 475**

**Morrisville, North Carolina 27560**

(Address of Principal Executive Offices)

**(212) 554-4484**

(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2b under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities filed pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of Class** | **Trading Symbol(s)** | **Exchange Name** |
| Common Stock | TGTX | Nasdaq Capital Market |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2). Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

---

| | |
|:---|:---|
| **Item 5.07.** | **Submission of Matters to a Vote of Security Holders.** |

---

On Thursday, June 11, 2026, at 9:30 a.m. Eastern Time, by means of an online meeting platform, TG Therapeutics, Inc. (the "Company") held its 2026 Annual Meeting. Stockholders representing 113,003,414, or 73.81%, of the 153,093,879 outstanding shares were present in person or by proxy, constituting a quorum under applicable law. Proxies were solicited by the Company pursuant to Regulation 14A under the Securities Exchange Act of 1934, as amended (the "SEC"). Each of the proposals below are described in detail in the Company's definitive proxy statement on Schedule 14A for the 2026 Annual Meeting, filed with the SEC on April 30, 2026. At the 2026 Annual Meeting, all of the proposals were approved except for proposal 3.

The results are as follows:

**Proposal 1**

The votes with respect to the election of the six directors to hold office until the 2027 annual meeting were as follows:

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| **Director** | **Votes For** | **% Voted For** | **Votes Withheld** | **% Voted Withheld** | **Broker Non-Votes** |
| Michael S. Weiss | 72172630 | 88.63% | 9260279 | 11.37% | 31570505 |
| Laurence N. Charney | 68135448 | 83.67% | 13297461 | 16.33% | 31570505 |
| Yann Echelard | 64110661 | 78.73% | 17322248 | 21.27% | 31570505 |
| Kenneth Hoberman | 53354717 | 65.52% | 28078192 | 34.48% | 31570505 |
| Daniel Hume | 63979535 | 78.57% | 17453374 | 21.43% | 31570505 |
| Sagar Lonial, MD | 44666544 | 54.85% | 36766365 | 45.15% | 31570505 |

---

**Proposal 2**

The vote with respect to the ratification of KPMG LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026 was as follows:

---

| | | | |
|:---|:---|:---|:---|
| **Total Votes For** | **Total Votes Against** | **Abstentions** | **Broker Non-Votes** |
| 112329330 | 531758 | 142326 | -- |

---

**Proposal 3**

The advisory vote to approve the compensation of the Company's named executive officers was as follows:

---

| | | | |
|:---|:---|:---|:---|
| **Total Votes For** | **Total Votes Against** | **Abstentions** | **Broker Non-Votes** |
| 31905837 | 48858169 | 668903 | 31570505 |

---

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | <u>TG THERAPEUTICS, INC.</u> | <u>TG THERAPEUTICS, INC.</u> |
|  | (Registrant) | (Registrant) |
| Date: June 12, 2026 | By: | /s/ Sean A. Power |
|  | Name: | Sean A. Power |
|  | Title: | Chief Financial Officer |

---